Lakewood-Amedex Highlights Nu-3's Resistance Data Amid Federal AMR Push
Event summary
- Lakewood-Amedex presented Nu-3 resistance data aligning with PACCARB's National Action Plan on AMR.
- Nu-3 demonstrated no induced resistance in serial passage experiments and broad-spectrum activity against diverse bacterial resistance mechanisms.
- The company's Bisphosphocin® platform targets bacterial membrane disruption, offering a unique physical mechanism of action.
The big picture
Lakewood-Amedex's data release comes amid heightened federal focus on antimicrobial resistance, with PACCARB's National Action Plan serving as a roadmap for U.S. government efforts. The company's Bisphosphocin® platform represents one of several emerging therapeutic avenues designed to bypass traditional resistance mechanisms, addressing a critical gap in the treatment of infections like MRSA and VRE.
What we're watching
- Regulatory Tailwinds
- How PACCARB's National Action Plan will accelerate development timelines for Nu-3 and similar AMR-focused therapies.
- Clinical Validation
- Whether Nu-3's resistance profile in lab settings translates to Phase 2 trial success against infected diabetic foot ulcers.
- Market Differentiation
- The pace at which Lakewood-Amedex can position Bisphosphocin® as a leading platform for combating antibiotic-resistant bacterial strains.
Related topics